Research
Hormonal
GLP-1 agonist semaglutide produces significant weight loss (12.7%) and improves cardiometabolic risk in adults with obesity, with transient mild-to-moderate nausea and diarrhea as primary side effects.
If you have obesity and meet the criteria (BMI ≥30 or ≥27 with complications), discuss GLP-1 agonists like semaglutide with your doctor. This medication can lead to substantial weight loss (around 12.7% in studies) and improves blood sugar and heart disease risk. Common side effects like nausea or diarrhea are usually temporary and manageable.
GoodSupportsHIGH confidence
For example, the GLP-1 agonist semaglutide reduced body weight by 12.7% (and also reduced blood sugar and CVD risk) in individuals with obesity. Nausea and diarrhoea were the most common adverse events with semaglutide; they were typically transient and mild-to-moderate in severity and subsided with time.
Why this rating
Cites a specific NEJM study (Wilding et al., 2021) referenced in the text, implying high-quality RCT data.
Source
Obesity
Pascal Bovet et al. · 2023
DOI 10.4324/9781003306689-12
book_chapterCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery (gastric banding, bypass, sleeve gastrectomy) results in large weight loss, induces remission of type-2 diabetes and hypertension, and increases life expectancy.Good
- A 5-10% weight loss in adults is often sufficient to obtain substantial health benefits from decreasing obesity-related comorbidities, challenging the goal of maximum weight loss in the shortest time.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →